Similar articles

• Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.

  Suzuki E, Kanba S, Nibuya M, Koshikawa H, Nakaki T, Yagi G. Suzuki E, et al. Biol Psychiatry. 1992 Feb 15;31(4):357-64. doi: 10.1016/0006-3223(92)90229-s. Biol Psychiatry. 1992. PMID: 1348430 Clinical Trial.
• Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.

  Suzuki E, Kanba S, Koshikawa H, Nibuya M, Yagi G, Asai M. Suzuki E, et al. J Psychiatry Neurosci. 1996 May;21(3):167-71. J Psychiatry Neurosci. 1996. PMID: 8935328 Free PMC article.
• Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.

  Davila R, Gonzalez MA, Zumarraga M, Andia I, Guimon J, Silva RR, Friedhoff AJ. Davila R, et al. Biol Psychiatry. 1995 Aug 15;38(4):267-9. doi: 10.1016/0006-3223(95)00245-C. Biol Psychiatry. 1995. PMID: 8547450 No abstract available.
• Atypical antipsychotics: mechanism of action.

  Seeman P. Seeman P. Can J Psychiatry. 2002 Feb;47(1):27-38. Can J Psychiatry. 2002. PMID: 11873706 Review.
• Dopamine receptors and the dopamine hypothesis of schizophrenia.

  Seeman P. Seeman P. Synapse. 1987;1(2):133-52. doi: 10.1002/syn.890010203. Synapse. 1987. PMID: 2905529 Review.